You are here

Home » The Childhood Cancer Report »

The 2026 Childhood Cancer Report

From diagnosis to research: measuring momentum in the search for cures

Cover of The Childhood Cancer Report, featuring a black and white image of a child with cancer holding a stuffed animal

Download the Report

You are here

Home » The Childhood Cancer Report

References

  1. “Study of Leukemia Biology Needed to Improve Treatment, Pinkel Says,” The Cancer Letter 4, no. 14 (1978): 6, https://cancerletter.com/issues/19780407/.
  2. GBD 2017 Childhood Cancer Collaborators, “The Global Burden of Childhood and Adolescent Cancer In 2017: An Analysis of the Global Burden of Disease Study 2017,” The Lancet Oncology 20, no. 9 (2019), https://pubmed.ncbi.nlm.nih.gov/31371206/.
  3. “Cancer Stat Facts,” National Cancer Institute, accessed April 10, 2026, https://seer.cancer.gov/statfacts/.
  4. “Childhood Cancers by International Classification of Childhood Cancer (ICCC),” U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://gis.cdc.gov/Cancer/USCS/#/special-topic/childhood-cancer-iccc?cancer=87&indicator=value&timeperiod=1&sexes=1&races=1&tab=1&view=chart&xaxis=ages.
  5. “Childhood Cancers by International Classification of Childhood Cancer (ICCC),” U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://gis.cdc.gov/Cancer/USCS/#/special-topic/childhood-cancer-iccc?cancer=87&indicator=value&timeperiod=1&sexes=1&races=1&tab=1&view=chart&xaxis=ages.
  6. “People Diagnosed Before Age 20 and Alive (U.S. Prevalence) on January 1, 2022,” NCCR*Explorer, National Cancer Institute, accessed October 14, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=1&data_type=5&graph_type=11&compareBy=sex&chk_sex_1=1&series=9&age_at_prev=1&advopt_precision=1#resultsRegion1.
  7. “Childhood Cancers by International Classification of Childhood Cancer (ICCC),” U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://gis.cdc.gov/Cancer/USCS/#/special-topic/childhood-cancer-iccc?cancer=87&indicator=value&timeperiod=1&sexes=1&races=1&tab=2&view=table&xaxis=ages.
  8. “Age and Cancer Risk,” National Cancer Institute, accessed September 18, 2025, https://www.cancer.gov/about-cancer/causes-prevention/risk/age.
  9. “All Cancer Sites Combined Recent Trends in SEER Age-Adjusted Incidence Rates, 1975-2023,” Cancer Statistics Explorer Network SEER* Explorer, National Cancer Institute, accessed June 15, 2026, https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_1=1&rate_type=2&race=1&age_range=15&hdn_stage=101&advopt_precision=1&advopt_show_ci=on.
  10. “Rate of Cancer Deaths in the United States, 2024,” Cancer Statistics: Mortality All Cancer Sites Combined, United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://gis.cdc.gov/cancer/USCS/#/special-topic/childhood-cancer-primary-site?datatype=2&cancer=1&indicator=value&timeperiod=26&sexes=1&races=1&ages=21&tab=1&view=chart.
  11. “All Cancer Sites Combined: Recent Trends in U.S. Age-Adjusted Mortality Rates, 2000-2024,” Cancer Statistics Explorer Network SEER* Explorer, National Cancer Institute, accessed June 15, 2026, https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=age_range&chk_age_range_15=15&rate_type=2&sex=1&race=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on.
  12. Joachim Worthington et al., “Covid-Related Disruptions to Colorectal Cancer Screening, Diagnosis, and Treatment Could Increase Cancer Burden in Australia and Canada: A Modelling Study,” PLOS ONE 19, no. 4 (2024): e0296945, https://doi.org/10.1371/journal.pone.0296945.
  13. “Childhood Cancers by International Classification of Childhood Cancer (ICCC),” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://gis.cdc.gov/cancer/USCS/#/special-topic/childhood-cancer-iccc?cancer=87&indicator=count&timeperiod=1&sexes=1&races=1&tab=1&view=chart&x-axis=ages.
  14. “United States Cancer Cases and Death Statistics at a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://gis.cdc.gov/cancer/USCS/#/special-topic/childhood-cancer-iccc?cancer=87&indicator=count&timeperiod=1&sexes=3&races=1&tab=1&view=chart&xaxis=ages.
  15. “United States Cancer Cases and Death Statistics at a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  16. “Cancer Site Comparison 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute; Accessed October 14, 2025 https://nccrexplorer.ccdi.cancer.gov/application.html?site=1&data_type=4&graph_type=5&compareBy=sex&chk_sex_3=3&chk_sex_2=2&series=9&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on.
  17. “Rate of Cancer Deaths in the United States, 2023,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessedJune 15, 2026, https://www.cdc.gov/cancer/dataviz.
  18. “Long -Term Trends in SEER Age-Adjusted Incidence Rates, 1975-2023,” Cancer Statistics Explorer Network SEER*Explorer, National Cancer Institute, accessed March 6, 2026, https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=1&compareBy=age_range&chk_age_range_15=15&rate_type=2&sex=1&race=1&advopt_precision=1&advopt_show_ci=on.
  19. Steve Friedman and Serban Negoita, “History of the Surveillance, Epidemiology, and End Results (SEER) Program,” J Natl Cancer Inst Monogr. 65 (2024): 105-109, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300016/.
  20. “Facts and Figures,” Congressional Childhood Cancer Caucus, accessed December 11, 2025, https://childhoodcancer-mccaul.house.gov/facts-and-figures.
  21. Katherine Schneider et al., “Li-Fraumeni syndrome,” in GeneReviews (University of Washington, 1999), https://www.ncbi.nlm.nih.gov/books/NBK1311.
  22. Jared Marsh, “Danger: Pesticides Raise Death Risk 60% for Kids with Leukemia,” University of California San Francisco, September 17, 2025, https://www.ucsf.edu/news/2025/09/430731/danger-pesticides-raise-death-risk-60-kids-leukemia.
  23. Julianne Byrne et al., “Childhood Cancer Survivors’ Knowledge of Their Diagnosis and Treatment,” Annals of Internal Medicine 110, no. 5 (1989): 400–403, https://doi.org/10.7326/0003-4819-110-5-400.
  24. E. B. D. Neuhauser et al., “Irradiation Effects of Roentgen Therapy on the Growing Spine,” Radiology 59, no. 5 (1952): 637–643, https://doi.org/10.1148/59.5.637.
  25. Jeanne Harvey et al., “Providing Quality Care in Childhood Cancer Survivorship: Learning from the Past, Looking to the Future,” Journal of Pediatric Oncology Nursing 16, no. 3 (1999): 117-125, https://doi.org/10.1016/S1043-4542(99)90009-7.
  26. G. J. D’Angio, “Pediatric Cancer in Perspective: Cure Is Not Enough,” Cancer 35, no. 3 (1975): 866–870, https://doi.org/10.1002/1097-0142(197503)35:3+<866::AID-CNCR2820350703>3.0.CO;2-F.
  27. Donatus U. Ekwueme et al., “Annual Out-of-Pocket Expenditures and Financial Hardship Among Cancer Survivors Aged 18–64 Years—United States, 2011–2016,” Weekly 68, no. 22 (2019): 494–499, https://doi.org/10.15585/mmwr.mm6822a2.
  28. “Childhood Cancer Survivor Study: An Overview,” National Cancer Institute, accessed December 11, 2025, https://www.cancer.gov/types/childhood-cancers/ccss.
  29. Jelena Roganovic, “Late Effects of the Treatment of Childhood Cancer,” World Journal of Clinical Cases 13, no. 7 (2025), https://doi.org/10.12998/wjcc.v13.i7.98000.
  30. “Late Effects of Treatment for Childhood Cancer (PDQ®)–Patient Version,” National Cancer Institute, accessed December 11, 2025, https://www.cancer.gov/types/childhood-cancers/late-effects-pdq.
  31. “Survivorship Guidelines: Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers,” Children’s Oncology Group, accessed December 11, 2025, https://childrensoncologygroup.org/survivorshipguidelines.
  32. K. E. Effinger et al., “Current Pediatric Cancer Survivorship Practices: A Report from the Children’s Oncology Group,” Journal of Cancer Survivorship 17 (2022): 1139–1148, https://doi.org/10.1007/s11764-021-01157-w.
  33. “Care for Childhood Cancer Survivors,” National Cancer Institute, accessed December 11, 2025, https://www.cancer.gov/about-cancer/coping/survivorship/child-care.
  34. “About CCSS,” Childhood Cancer Survivor Study, St. Jude Children’s Research Hospital, accessed December 11, 2025, https://ccss.stjude.org/about-the-study.html.
  35. Leslie L. Robison et al., “Study Design and Cohort Characteristics of the Childhood Cancer Survivor Study: A Multi-Institutional Collaborative Project,” Medical and Pediatric Oncology 38, no. 4 (2002): 229–239, https://doi.org/10.1002/mpo.1316.
  36. “Big 5 Challenges Kenya Faces in Fighting Childhood Cancer,” Kenyatta University Teaching, Referral, and Research Hospital, accessed December 2025, https://www.kutrrh.go.ke/big-5-challenges-kenya-faces-in-fighting-childhood-cancer/.
  37. “Childhood Cancer,” International Agency for Research on Cancer, World Health Organization, accessed December 2025, https://www.iarc.who.int/cancer-type/childhood-cancer/.
  38. “Childhood Cancer,” World Health Organization, accessed December 11, 2025, https://www.who.int/news-room/fact-sheets/detail/cancer-in-children.
  39. “Childhood Cancer,” World Health Organization, accessed December 11, 2025, https://www.who.int/news-room/fact-sheets/detail/cancer-in-children.
  40. “Global Initiative for Childhood Cancer,” Union for International Cancer Control, accessed December 2025, https://www.uicc.org/what-we-do/advocacy/working-together/global-initiative-childhood-cancer.
  41. “The Burden: Childhood Cancer,” The Cancer Atlas, accessed December 11, 2025, https://canceratlas.cancer.org/burden-of-cancer/childhood-cancer/.
  42. “The Burden: Childhood Cancer,” The Cancer Atlas, accessed December 11, 2025, https://canceratlas.cancer.org/burden-of-cancer/childhood-cancer/.
  43. “S.3312 - 102nd Congress (1991-1992): Cancer Registries Amendment Act,” Congress.gov, accessed December 11, 2025, https://www.congress.gov/bill/102nd-congress/senate-bill/3312.
  44. “NPCR Timeline,” National Program of Cancer Registries, Centers for Disease Control and Prevention, accessed December 11, 2025, https://www.cdc.gov/national-program-cancer-registries/about/npcr-timeline.html.
  45. “S.3312 - 102nd Congress (1991-1992): Cancer Registries Amendment Act,” Congress.gov, accessed December 11, 2025, https://www.congress.gov/bill/102nd-congress/senate-bill/3312.
  46. “How Cancer Registries Work,” National Program of Cancer Registries, Centers for Disease Control and Prevention, accessed December 11, 2025, https://www.cdc.gov/national-program-cancer-registries/about/how-cancer-registries-work.html.
  47. Stephanie Hill, NAACCR, Personal Communication/Phone Interview, June 18, 2025.
  48. “Cancer Surveillance Programs and Data Tracking,” American Cancer Society, accessed December 11, 2025,https://www.cancer.org/cancer/preparing-for-treatment/cancer-surveillance-programs-and-data-tracking.html.
  49. “Pediatric Oncology Drug Approvals,” U.S. Food and Drug Administration Oncology Center of Excellence, accessed October 29, 2025, https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals.
  50. “Oncology (Cancer)/Hematologic Malignancies Approval Notifications,” U.S. Food and Drug Administration, accessed October 29, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications.
  51. Siddhartha Mukherjee, The Emperor of All Maladies: A Biography of Cancer (Scribner, 2010), Part Two: “An Impatient War.”
  52. “All Cancer Sites Combined: Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2023,” Cancer Statistics Explorer Network SEER*Explorer, National Cancer Institute; accessed October 29, 2025, https://seer.cancer.gov/statistics-network/explorer/application.html.
  53. Christian P. Kratz, “Re-Envisioning Genetic Predisposition to Childhood and Adolescent Cancers,” Nature Reviews Cancer 25 (2025): 109-128, https://www.nature.com/articles/s41568-024-00775-7.
  54. Kinga Panuciak et al. “Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias,” Cells 11, no. 1(2022): 139, https://pmc.ncbi.nlm.nih.gov/articles/PMC8749975/.
  55. “Cancer Site Comparison: Recent Trends in U.S. Age-Adjusted Mortality Rates, 2000-2024,” Cancer Statistics Explorer Network SEER*Explorer, National Cancer Institute, accessed December 5, 2025, https://seer.cancer.gov/statistics-network/explorer/application.html?site=96&data_type=2&graph_type=2&compareBy=site&chk_site_20=20&chk_site_47=47&chk_site_40=40&sex=1&race=1&age_range=15&advopt_precision=1&advopt_show_ci=on&advopt_show_count=on#resultsRegion0.
  56. “Acute Myeloid Leukemia (AML): Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2023,” Cancer Statistics Explorer Network SEER*Explorer, National Cancer Institute, accessed December 5, 2025, https://seer.cancer.gov/statistics-network/explorer/application.html?site=96&data_type=1&graph_type=2&compareBy=age_range&chk_age_range_15=15&rate_type=2&sex=1&race=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&advopt_show_count=on#resultsRegion0.
  57. “I. Leukemias: 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute, accessed December 5, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=100&data_type=4&graph_type=5&compareBy=age_range&chk_age_range_2=2&chk_age_range_3=3&chk_age_range_4=4&chk_age_range_5=5&chk_age_range_6=6&series=9&sex=1&race=1&advopt_precision=1&advopt_show_ci=on.
  58. “II. Lymphomas: 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute, accessed December 5, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=200&data_type=4&graph_type=5&compareBy=age_range&chk_age_range_2=2&chk_age_range_3=3&chk_age_range_4=4&chk_age_range_5=5&chk_age_range_6=6&series=9&sex=1&race=1&advopt_precision=1&advopt_show_ci=on#resultsRegion1.
  59. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  60. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  61. “Childhood Cancers by International Classification of Childhood Cancer (ICCC),” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  62. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  63. “Treating Childhood Leukemia,” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/types/leukemia-in-children/treating.html#:~:text=How%20is%20childhood%20leukemia%20treated,with%20Acute%20Promyelocytic%20Leukemia%20(APL).
  64. “USAN Council,” American Medical Association, accessed December 5, 2025, https://www.ama-assn.org/about/united-states-adopted-names-usan/usan-council.
  65. “Chemotherapy for Childhood Leukemia,” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/types/leukemia-in-children/treating/chemotherapy.html.
  66. “Stem Cell Transplantation for Leukemia in Children,” NYU Langone Health, accessed December 5, 2025, https://nyulangone.org/conditions/leukemia-in-children/treatments/stem-cell-transplantation-for-leukemia-in-children.
  67. Maria Moschovi and Charikleia Kelaidi, “Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors,” International Journal of Molecular Sciences 22, no. 15 (2021): 7806, https://pmc.ncbi.nlm.nih.gov/articles/PMC8345932/#:~:text=Overall%2C%20in%20terms%20of%20overall,time%20point%20of%2012%20months.
  68. “Pediatric Oncology Drug Approvals,” U.S. Food and Drug Administration, accessed December 5, 2025, https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals.
  69. Devon Carter, “Chronic versus Acute Leukemia: Different Diagnoses, Different Treatments,” The University of Texas MD Anderson Cancer Center, accessed December 5, 2025, https://www.mdanderson.org/cancerwise/what-is-the-difference-between-chronic-and-acute-leukemia--different-diagnoses--different-treatments.h00-159461634.html.
  70. “Pediatric Lymphomas,” Memorial Sloan Kettering Cancer Center, accessed December 5, 2025, https://www.mskcc.org/pediatrics/cancer-care/types/pediatric-lymphomas.
  71. “Targeted Therapy Drugs for Childhood Leukemia,” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/types/leukemia-in-children/treating/targeted-therapy.html.
  72. Hannah J Uckelmann et al., “Therapeutic Targeting of Preleukemia Cells in a Mouse Model of NPM1 Mutant Acute Myeloid Leukemia,” Science 367, no. 6477 (2020): 586-590, https://pmc.ncbi.nlm.nih.gov/articles/PMC7754791/.
  73. Zhang, W. et al. “Advances in CAR-T Therapy for Pediatric Leukemia.” Frontiers in Oncology, 9 (2020), https://gis.cdc.gov/Cancer/USCS/#/explore/mortality?cancer=1&datatype=2&dataset=standard&indicator=value&area=1&timeperiod=26&-sexes=1&races=1&ages=23&tab=1&view=map&xaxis=sexes&shownational=true/.
  74. “BLINCYTO® Is a BiTE® Therapy That Binds CD3 and CD19,” Amgen, accessed December 5, 2025, https://www.blincytohcp.com/about-blincyto/mechanism-of-action.
  75. Timothy M. Pierpoint et al., “Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy,” Frontier Oncology 8 (2018), https://doi.org/10.3389/fonc.2018.00163.
  76. “Immunotherapy for Childhood Leukemia,” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/types/leukemia-in-children/treating/immunotherapy.html.
  77. Nazma Hanif and Faiz Anwer, “Rituximab,” StatPearls [Internet], National Library of Medicine, accessed December 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK564374/#:~:text=Rituximab%20is%20an%20anti%2DCD20,for%20use%20in%20several%20conditions.&text=As%20a%20single%20agent%20in%20low%2Dgrade%20non%2Dprogressive/,and%20Prednisolone%20(CVP)%20chemotherapy.
  78. Anurekha G. Hall and Rachel E. Rau, “Blinatumomab Use in Pediatric B-ALL: Where Are We Now?” Blood Advances 9, no. 15 (2025): 3946–3954, https://ashpublications.org/bloodadvances/article/9/15/3946/537699/Blinatumomab-use-in-pediatric-B-ALL-where-are-we.
  79. Carmen Phillips, “Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL,” National Cancer Institute, published on February 13, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2025/childhood-leukemia-blincyto-first-treatment.
  80. Michele Gottardi et al., “Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin,” Cancers 13, no. 18 (2021): 4566, https://pmc.ncbi.nlm.nih.gov/articles/PMC8469571/#:~:text=It%20(%20Gemtuzumab%20Ozogamicin%20)%20targets%20leukemic,chemotherapy%20during%20induction%20regimens%2C%20pre%2D%20and%20post%2Dtransplantation.
  81. Edward Winstead, “Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents,” National Cancer Institute, published December 15, 2022, https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-brentuximab-children-hodgkin-lymphoma.
  82. Quinn T. Ostrom et al. “CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018,” Neuro-Oncology 24, no. Supplement_3 (2022), https://academic.oup.com/neuro-oncology/article/24/Supplement_3/iii1/6692860.
  83. “Pediatric Brain Tumors,” Mayo Clinic, accessed October 29, 2025, https://www.mayoclinic.org/diseases-conditions/pediatric-brain-tumor/diagnosis-treatment/drc-20361706.
  84. “III. Central Nervous System Neoplasms (Malignant): 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute, accessed October 29, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=300&data_type=4&graph_type=5&compareBy=sex&chk_sex_1=1&series=9&race=1&age_range=1&advopt_precision=1&adopt_show_ci=on#resultsRegion0.
  85. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  86. “PBTF Childhood and Adolescent Brain Tumor Facts,” Neuro-Oncology 27, no. Supplement_1, (2025), https://doi.org/10.1093/neuonc/noaf214.
  87. “Proton Therapy for Brain Tumors,” Johns Hopkins Medicine, accessed October 29, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/brain-tumor/proton-therapy.
  88. Clara Guido et al., “Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers,” Diagnostics 12, no. 1: 173, https://doi.org/10.3390/diagnostics12010173.
  89. Mark M. Souweidane et al., “Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: A Single-Centre, Dose-Escalation, Phase 1 Trial,” The Lancet Oncology 19, no. 8 (2018): 1040–1050, https://doi.org/10.1016/S1470-2045(18)30322-X.
  90. Kelsi M. Chesney et al., “The Role of Focused Ultrasound for Pediatric Brain Tumors: Current Insights and Future Implications on Treatment Strategies,” Child’s Nervous System 40 (2024): 2333–2344, https://doi.org/10.1007/s00381-024-06413-9.
  91. Darcy A. Krueger et al., “Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis,” The New England Journal of Medicine 363, no. 19 (2010): 1801-1811, https://www.nejm.org/doi/full/10.1056/NEJMoa1001671.
  92. David N. Franz et al., “Everolimus for Subependymal Giant Cell Astrocytoma: 5-Year Final Analysis,” Ann Neurol 78, no. 6 (2015): 929-938, https://pmc.ncbi.nlm.nih.gov/articles/PMC5063160/.
  93. Edward Winstead, “Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations,” National Cancer Institute, accessed October 29, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors.
  94. Thomas Pfefer et al, “Immunometabolites and Cancer: The Role of 2-Hydroxyglutarate, Succinate, Fumarate and Itaconate in Tumour Development and Anti-Tumour Immunity,” Immunology Letters 279 (2026), https://doi.org/10.1016/j.imlet.2026.107153.
  95. “FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a susceptible IDH1 or IDH2 Mutation,” U.S. Food and Drug Administration, accessed October 29, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation.
  96. Cleiton Formentin et al., “Posterior fossa tumors in children: current insights,” European Journal of Pediatrics 182 (2023): 4833–4850, https://doi.org/10.1007/s00431-023-05189-5.
  97. Lindsay B. Kilburn et al., “The Type II RAF Inhibitor Tovorafenib in Relapsed/Refractory Pediatric Low-Grade Glioma: The Phase 2 Firefly-1 Trial,” Nature Medicine 30 (2024): 207-217, https://www.nature.com/articles/s41591-023-02668-y.
  98. Kilburn LB. “FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAFAltered Pediatric LowGrade Glioma.” Clinical Cancer Research 31(8) (2025). https://aacrjournals.org/clincancerres/article-abstract/31/8/1383/754518/FDA-Approval-Summary-Tovorafenib-for-Relapsed-or?redirectedFrom=fulltext.
  99. Xiaonan Zhao et al., “NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome,” JCO Precision Oncology 5 (2021): 204-214, https://ascopubs.org/doi/10.1200/PO.20.00250.
  100. “Pediatric Oncology Drug Approvals,” U.S. Food and Drug Administration, accessed October 29, 2025, https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals.
  101. Mark N. Stein et al., “First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors,” Clinical Cancer Research 23, no. 15 (2017): 4163–4169, https://aacrjournals.org/clincancerres/article/23/15/4163/257537/First-in-Human-Clinical-Trial-of-Oral-ONC201-in.
  102. Chi, Anthony S., et al. “Dordaviprone in diffuse midline glioma: early results.” The New England Journal of Medicine (2025). https://pubmed.ncbi.nlm.nih.gov/37679511/.
  103. Northcott, Paul A, “The whole-genome landscape of medulloblastoma subtypes,” Nature, 2017 Jul 20, https://pmc.ncbi.nlm.nih.gov/articles/PMC5905700/.
  104. Brent A. Orr, “Pathology, diagnostics, and classification of medulloblastoma,” Brain Pathology 30, no. 3 (2020): 664-678, https://pmc.ncbi.nlm.nih.gov/articles/PMC7317787/.
  105. “Medulloblastoma: Diagnosis and Treatment,” National Cancer Institute, accessed October 29, 2025, https://www.cancer.gov/rare-brain-spine-tumor/tumors/medulloblastoma.
  106. Edwin S. Kulubya et al., “Advances in the Treatment of Pediatric Brain Tumors,” Children (Basel) 10, no. 1 (2022): 62, https://pmc.ncbi.nlm.nih.gov/articles/PMC9856380/.
  107. Linda Wang, “Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain Cancer,” National Cancer Institute, accessed October 29, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2025/car-t-cell-therapy-gd2-diffuse-midline-gliomas.
  108. Edwin S. Kulubya et al., “Advances in the Treatment of Pediatric Brain Tumors,” Children (Basel) 10, no. 1 (2022): 62, https://pmc.ncbi.nlm.nih.gov/articles/PMC9856380/.
  109. Gregory K. Friedman et al., “Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas,” The New England Journal of Medicine 384, no. 17 (2021): 1613-1622, DOI: 10.1056/NEJMoa2024947.
  110. “Neuroblastoma,” Cleveland Clinic, accessed October 30, 2025, https://my.clevelandclinic.org/health/diseases/14390-neuroblastoma.
  111. “Survival Rates by Risk Group for Neuroblastoma,” American Cancer Society, accessed October 11, 2025, https://www.cancer.org/cancer/types/neuroblastoma/detection-diagnosis-staging/survival-rates.html.
  112. National Childhood Cancer Registry Explorer (NCCR*Explorer), National Childhood Cancer Registry & National Cancer Institute, accessed December 4, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=400&data_type=4&graph_type=5&compareBy=age_range&chk_age_range_2=2&chk_age_range_3=3&chk_age_range_4=4&chk_age_range_5=5&chk_age_range_6=6&series=9&sex=1&race=1&advopt_precision=1&advopt_show_ci=on#resultsRegion1.
  113. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  114. Sidharth Mahapatra and Kishore B. Challagundla, “Neuroblastoma,” StatPearls [Internet], National Library of Medicine, accessed December 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK448111/.
  115. “Survival Rates by Risk Group for Neuroblastoma,” American Cancer Society, accessed December 4, 2025, https://www.cancer.org/cancer/types/neuroblastoma/detection-diagnosis-staging/survival-rates.html.
  116. “MIBG Treatment,” Texas Children’s Hospital, accessed December 4, 2025, https://www.texaschildrens.org/content/conditions/mibg-treatment#:~:text=What%20is%20MIBG%20therapy?,better%20tolerated%20than%20other%20therapies.TexasChildren’s.
  117. “Researchers Show Lorlatinib is Safe, Effective for Patients with High-Risk Neuroblastoma,” Children’s Hospital of Philadelphia, accessed December 4, 2025, https://www.chop.edu/news/researchers-show-lorlatinib-safe-effective-patients-high-risk-neuroblastoma.
  118. Jianxiong Jiang and Ying Yu, “Eflornithine for Treatment of High-Risk Neuroblastoma,” Trends in Pharmacological Sciences 45, no. 6 (2024): 577-578, https://pmc.ncbi.nlm.nih.gov/articles/PMC11162306/.
  119. Atsushi Makimoto et al., “Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects,” Cancers (Basel) 16, no. 3 (2024): 544, https://pmc.ncbi.nlm.nih.gov/articles/PMC10854948/.
  120. James Stallard, “Reduced Radiation for Neuroblastoma Could Lessen Children’s Side Effects Later,” Memorial Sloan Kettering Cancer Center, accessed December 4, 2025, https://www.mskcc.org/news/reduced-radiation-dose-neuroblastoma-could-spare-children-complications-later.
  121. Yaël P. Mossé et al., “Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma,” JCO Precision Oncology 9 (2025), https://doi.org/10.1200/PO-24-00886.
  122. Junko Takita, “Molecular Basis and Clinical Features of Neuroblastoma.” JMA Journal 4, no. 4 (2021): 321-331, https://pmc.ncbi.nlm.nih.gov/articles/PMC8580727/.
  123. “FDA Approves First Therapy for High-Risk Neuroblastoma,” National Cancer Institute, accessed December 4, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2015/dinutuximab-neuroblastoma.
  124. Rosa Nguyen and Carol J Thiele, “Immunotherapy Approaches Targeting Neuroblastoma,” Current Opinion in Pediatrics 33, no. 1 (2021): 19-25, https://pmc.ncbi.nlm.nih.gov/articles/PMC8818321/.
  125. Renaissance Pharma Limited, an Essential Pharma Company, Secures FDA Fast Track Designation and IND Clearance for Daretabart (hu1418K322A) in High-Risk Neuroblastoma,” Yahoo! Finance, April 14, 2026, https://sg.finance.yahoo.com/news/renaissance-pharma-limited-essential-pharma-060000802.html?guccounter=1.
  126. “Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version,” National Cancer Institute, accessed October 30, 2025, https://www.cancer.gov/types/soft-tissue-sarcoma/patient/child-soft-tissue-treatment-pdq.
  127. Vanessa Eulo et al., “Secondary Sarcomas: Biology, Presentation, and Clinical Care,” American Society of Clinical Oncology Educational Book 40 (2020): 463-474, https://ascopubs.org/doi/10.1200/EDBK_280985.
  128. Regan F. Williams et al., “Pediatric Sarcomas,” Surgical Clinics of North America 96, no. 5 (2016): 1107-1125, https://pubmed.ncbi.nlm.nih.gov/27542645/.
  129. Audra J. Reiter, “Survival Outcomes in Pediatric Patients with Metastatic Ewing Sarcoma Who Achieve a Rapid Complete Response of Pulmonary Metastases,” Pediatric Blood & Cancer 71, no. 7 (2024), https://pmc.ncbi.nlm.nih.gov/articles/PMC11116042/.
  130. “VIII. Bone Tumors: 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute, accessed October 30, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=800&data_type=4&graph_type=5&compareBy=sex&chk_sex_1=1&series=9&race=1&age_range=2&advopt_precision=1&advopt_show_ci=on#resultsRegion0.
  131. “IX. Soft Tissue Tumors: 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute, accessed October 30, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=900&data_type=4&graph_type=5&compareBy=age_range&chk_age_range_2=2&chk_age_range_3=3&chk_age_range_4=4&chk_age_range_5=5&chk_age_range_6=6&series=9&sex=1&race=1&advopt_precision=1&advopt_show_ci=on#resultsRegion1.
  132. “Childhood Cancers by International Classification of Childhood Cancer (ICCC),” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  133. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  134. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, Accessed June 15, 2026 https://www.cdc.gov/cancer/dataviz.
  135. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  136. “The Latest in Limb-Sparing Techniques for Pediatric Patients with Sarcoma,” Cleveland Clinic, Consult QD, accessed October 30, 2025, https://consultqd.clevelandclinic.org/the-latest-in-limb-sparing-techniques-for-pediatric-patients-with-sarcoma.
  137. Matthew M. Ladra and Torunn I. Yock, “Clinical Implications of Long-Term Survivorship in Soft Tissue Sarcomas,” Cancers (Basel) 6, no. 1 (2014): 112-127, https://pmc.ncbi.nlm.nih.gov/articles/PMC3980591/.
  138. Pampina Pilavaki et al., “Exploring the Landscape of Immunotherapy Approaches in Sarcomas,” Frontiers in Oncology 12 (2022), https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1069963/full.
  139. “Tazemetostat,” ScienceDirect, accessed October 30, 2025, https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/tazemetostat.
  140. Anthony B. El-Khoueiry et al., “Cabozantinib: An Evolving Therapy for Hepatocellular Carcinoma,” Cancer Treatment Reviews 98, no. 102221 (2021), https://doi.org/10.1016/j.ctrv.2021.102221.
  141. Guoshuang Shen et al., “Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development,” Journal of Hematology & Oncology 11, no. 120 (2018), https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0664-7.
  142. Suying Lu, “Safety and Feasibility of Anlotinib in Children with High Risk, Recurrent or Refractory Sarcomas: An Open-Label, Single-Centre, Single-Arm, Phase Ia/Ib Trial,” eClinicalMedicine 84, no. 103258 (2025), https://pmc.ncbi.nlm.nih.gov/articles/PMC12151220/.
  143. Michael Barbato et al., “FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer,” Clinical Cancer Research 30, no. 16 (2024): 3364-3370, https://pmc.ncbi.nlm.nih.gov/articles/PMC11326972/.
  144. Qinghua Jiang et al., “Entrectinib, a New Multi-Target Inhibitor for Cancer Therapy,” Biomedicine & Pharmacotherapy 150 (2022), https://www.sciencedirect.com/science/article/pii/S0753332222003638#:~:text=Entrectinib%20is%20a%20selective%2C%20oral.
  145. “Pediatric Oncology Drug Approvals,” U.S. Food & Drug Administration, accessed October 30, 2025, https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals.
  146. W. Du and J. Pogoriler, “Retinoblastoma Family Genes,” Oncogene 25 (2006): 5190–5200, https://www.nature.com/articles/1209651.
  147. Junne Kamihara et al., “Update on Retinoblastoma Predisposition and Surveillance Recommendations for Children,” Clinical Cancer Research 31, no. 9 (2025): 1573-1579, https://aacrjournals.org/clincancerres/article/31/9/1573/761249/Update-on-Retinoblastoma-Predisposition-and.
  148. Kirandeep Kaur and Bhupendra C. Patel, “Retinoblastoma,” StatPearls [Internet], National Library of Medicine, accessed December 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545276/.
  149. “V. Retinoblastoma: 5-Year Relative Survival Rates, 2015-2021,” NCCR*Explorer, National Cancer Institute, accessed December 5, 2025, https://nccrexplorer.ccdi.cancer.gov/application.html?site=500&data_type=4&graph_type=5&compareBy=age_range&chk_age_range_2=2&chk_age_range_3=3&chk_age_range_4=4&chk_age_range_5=5&chk_age_range_6=6&series=9&sex=1&race=1&advopt_precision=1&advopt_show_ci=on#resultsRegion1.
  150. “United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  151. Retinoblastoma,” StatPearls [Internet], National Library of Medicine, accessed March 5, 2026, https://www.ncbi.nlm.nih.gov/books/NBK545276/.
  152. “Treatments for Intraocular Retinoblastoma,” Canadian Cancer Society, last medical review September 2025, https://cancer.ca/en/cancer-information/cancer-types/retinoblastoma/treatment/intraocular-retinoblastoma.
  153. Chemotherapy for Retinoblastoma,” American Cancer Society, Date Accessed March 5, 2026, https://www.cancer.org/cancer/types/retinoblastoma/treating/chemotherapy.html.
  154. “External Beam Radiation Therapy for Cancer,” National Cancer Institute, accessed December 5, 2025, https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/external-beam#:~:text=It%20is%20a%20local%20treatment%2C%20which%20means,used%20to%20treat%20many%20types%20of%20cancer.
  155. “Children’s Retinoblastoma Eye Cancer Treatment,” Memorial Sloan Kettering Cancer Center, accessed December 5, 2025, https://www.mskcc.org/pediatrics/cancer-care/types/retinoblastoma/treatment.
  156. “Intra Arterial Chemotherapy for Retinoblastoma,” Children’s Hospital of Philadelphia, accessed December 5, 2025, https://www.chop.edu/treatments/intra-arterial-chemotherapy-iac-retinoblastoma#:~:text=What%20is%20intra%2Darterial%20chemotherapy,removal%20of%20the%20affected%20eye.
  157. “Radioactive Plaque (Brachytherapy),” World Eye Cancer Hope, accessed December 5, 2025, https://wechope.org/retinoblastoma/care/treatment/radiation-therapy/radioactive-plaque/#:~:text=A%20radioactive%20plaque%20looks%20a,cells%20so%20they%20cannot%20divide.
  158. “AACR Pediatric Cancer Progress Report,” American Association for Cancer Research, accessed March 5, 2026, https://cancerprogressreport.aacr.org/pediatric/pcpr25-contents/pcpr25-executive-summary/.
  159. AACR Pediatric Cancer Progress Report,” American Association for Cancer Research, Accessed March 5, 2026, https://cancerprogressreport.aacr.org/pediatric/pcpr25-contents/pcpr25-executive-summary/.
  160. “Neurofibromatosis Type 1 (NF1),” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes/neurofibromatosis-type-1.html.
  161. “NF1 Associated with More Cancer Types Than Previously Known,” National Cancer Institute, accessed December 5, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2021/nf1-associated-with-more-cancer-types.
  162. “Neurofibromatosis Type 2 (NF2),” Johns Hopkins Medicine, accessed December 5, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/neurofibromatosis/neurofibromatosis-type-2.
  163. M.A. Akbarzadeh et al., “Mirdametinib Approval for Neurofibromatosis Type 1 with Inoperable Plexiform Neurofibromas: The Journey of Mek Inhibitors,” ESMO Rare Cancers 3 (2025), https://doi.org/10.1016/j.esmorc.2025.100015.
  164. “Li-Fraumeni Syndrome (LFS),” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes/li-fraumeni-syndrome.html.
  165. “Li-Fraumeni Syndrome,” MedlinePlus, accessed March 5, 2026, https://medlineplus.gov/genetics/condition/li-fraumeni-syndrome/.
  166. “Li-Fraumeni Syndrome,” Children’s Hospital of Philadelphia, accessed December 5, 2025, https://www.chop.edu/conditions-diseases/li-fraumeni-syndrome#:~:text=References-,What%20is%20Li%2DFraumeni%20syndrome?,which%20tend%20to%20progress%20rapidly.
  167. “Li-Fraumeni Syndrome,” Cleveland Clinic, accessed December 5, 2025, https://my.clevelandclinic.org/health/diseases/22073-li-fraumeni-syndrome.
  168. “Beckwith–Wiedemann Syndrome (BWS),” American Cancer Society, accessed December 5, 2025, https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes/beckwith-wiedemann-syndrome.html.
  169. Suzanne P MacFarland et al., “Diagnosis of Beckwith-Wiedemann Syndrome in Children Presenting with Wilms Tumor,” Pediatric Blood Cancer 65, no. 10 (2018), https://pmc.ncbi.nlm.nih.gov/articles/PMC6107414/.
  170. “Beckwith–Wiedemann Syndrome,” Cleveland Clinic, accessed December 5, 2025, https://my.clevelandclinic.org/health/diseases/21993-beckwith-wiedemann-syndrome.
  171. “Pediatric Oncology Drug Approvals,” U.S. Food and Drug Administration, accessed March 6, 2026, https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals.
  172. Mark N. Fluchel et al., “Geography and the Burden of Care in Pediatric Cancers,” Pediatric Blood & Cancer 61, no. 11 (2014): 1918–1924, https://doi.org/10.1002/pbc.25170.
  173. “Survival at All Costs,” Family Reach, published August 2016, https://familyreach.org/wp-content/uploads/2016/08/16-FamilyReach-Survival-at-all-costs.pdf#:~:text=Rural%20parents%20required%20to%20travel%20more%20than,of%20missed%20work%20in%20the%20first%20month.
  174. Naveen Premnath et al., “Park the Parking,” JCO Oncology Practice 16, no. 5 (2020): 215–217, https://doi.org/10.1200/OP.20.00065.
  175. “Incident Rates by State, Childhood,” State Cancer Profiles, accessed June 15, 2026, https://statecancerprofiles.cancer.gov/map/index.php?statefips=00&areatype=state&datagroup=1&statistic=515&datatype=01&race=00&sex=0&year=0#results.
  176. “Death Rates by State, Childhood,” State Cancer Profiles, accessed June 15, 2026, https://statecancerprofiles.cancer.gov/map/index.php?statefips=00&areatype=state&datagroup=1&statistic=515&datatype=02&race=00&sex=0&year=0#results.
  177. “COG Institution Locations,” Children’s Oncology Group, accessed September 4, 2025, https://www.childrensoncologygroup.org/apps/instmap/default.aspx.
  178. “About Us,” Children’s Oncology Group, Accessed February 2026, https://childrensoncologygroup.org/about.
  179. “History of Texas Children’s Global HOPE Program,” Texas Children’s, accessed September 8, 2025, https://www.texaschildrens.org/texas-childrens-global-health/programs/global-hope.
  180. Arnold dela Cruz Paulino, MD, PhD, (Section Chief of Pediatric Radiation Oncology, University of Texas MD Anderson), Interview, June 2025.
  181. Todd Burus et al., “Travel-Time Disparities in Access to Proton Beam Therapy for Cancer Treatment,” JAMA Network Open 7, no. 5 (2024), https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2818955.
  182. Jennifer Maggiore (Executive Director, National Association of Proton Centers), Interview, July 2025.
  183. “Find a Proton Therapy Center Near You,” The National Association for Proton Therapy, accessed September 9, 2025, https://proton-therapy.org/findacenter/.
  184. Rebecca Gardner, MD, (St. Jude Children’s Research Hospital), Interview, June 26, 2025.
  185. “Find a KYMRIAH Treatment Center,” Kymriah, accessed July 2025, https://us.kymriah.com/treatment-center-locator.
  186. Justine M. Kahn et al., “An Investigation of Toxicities and Survival in Hispanic Children and Adolescents with ALL: Results From The Dana-Farber Cancer Institute ALL Consortium Protocol 05-001,” Pediatric Blood Cancer 65, no. 3 (2018), https://pubmed.ncbi.nlm.nih.gov/29090520/.
  187. Paula Aristizabal, “Diverse Populations and Enrollment in Pediatric Cancer Clinical Trials: Challenges and Opportunities,” Pediatric Blood Cancer 67, no. 11 (2020), doi: 10.1002/pbc.28296.
  188. Nadine J. Barrett et al., “Factors Associated with Biomedical Research Participation within Community-Based Samples Across 3 National Cancer Institute–Designated Cancer Centers,” Cancer 126, no. 5 (2020): 1077-1089, https://doi.org/10.1002/cncr.32487.
  189. United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  190. United States Cancer Cases and Death Statistics At a Glance,” United States Cancer Statistics: Data Visualizations, U.S. Centers for Disease Control and Prevention, accessed June 15, 2026, https://www.cdc.gov/cancer/dataviz.
  191. “Guidance on Coordinating Care Provided by Out-Of-State Providers for Children with Medically Complex Conditions,” Medicaid.gov, published October 20, 2021, https://www.medicaid.gov/federal-policy-guidance/2021-10-20/126981.
  192. “Medicaid and CHIP Eligibility Operations and Enrollment Snapshot,” Medicaid.gov, accessed July 2025, https://www.medicaid.gov/resources-for-states/downloads/eligib-oper-and-enrol-snap-aprl2025.pdf.
  193. Xu Ji et al., “Narrowing Insurance Disparities Among Children and Adolescents with Cancer Following the Affordable Care Act,” JNCI Cancer Spectrum 6, no. 1 (2022), doi: 10.1093/jncics/pkac006.
  194. “2024 Employer Health Benefits Survey,” KFF, published October 9, 2024, https://www.kff.org/health-costs/2024-employer-health-benefits-survey/.
  195. “Table I.F.19 Average Copayment (in dollars) for an Office Visit to a Specialist Physician per Employee Enrolled in a Health Insurance Plan That Had a Specialist Copayment at Private-Sector Establishments by Firm Size and Selected Characteristics: United States, 2019,” Agency for Healthcare Research and Quality, https://meps.ahrq.gov/data_stats/summ_tables/insr/national/series_1/2019/tif19.htm.
  196. James S. Miser et al., “The Health Care Utilization and Medical Costs in Long-Term Follow-Up of Children Diagnosed With Leukemia, Solid Tumor, or Brain Tumor: Population-Based Study Using the National Health Insurance Claims Data,” JMIR Public Health and Surveillance 9 (2023), https://pmc.ncbi.nlm.nih.gov/articles/PMC10020904/.
  197. Nicolas Iragorri et al., “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review,” Current Oncology 28, no. 2 (2021): 1216-1248, doi: 10.3390/curroncol28020117.
  198. Nancy Cruz Sitner, “How Socioeconomic Status Affects Diagnosis and Referral Pathways to HSCT,” Oncology Nursing Society, published June 18, 2024, https://www.ons.org/publications-research/voice/news-views/06-2024/how-socioeconomic-status-affects-diagnosis-and.
  199. Stergios Intzes et al., “Socioeconomic Status Is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients; Synthesis of Studies and Review of the Literature,” Mediterranean Journal of Hematology and Infectious Diseases 13, no. 1 (2021), https://doi.org/10.4084/MJHID.2021.006.
  200. Mark N. Fluchel et al., “Geography and the Burden of Care in Pediatric Cancers,” Pediatric Blood Cancer 61, no. 11 (2014): 1918–1924, doi: 10.1002/pbc.25170.
  201. Mallory F. Happ et al., “The Impact of Distance to Care on Unmet Nonmedical Costs Among Families of Children with Cancer,” Authorea (2025), doi: 10.22541/au.175562133.30864810/v1.
  202. Mark N. Fluchel et al., “Geography and the Burden of Care in Pediatric Cancers,” Pediatric Blood & Cancer 61 (2014): 1918–1924, https://doi.org/10.1002/pbc.25170.
  203. Jamie A. Weiner and Lisa K. Woodley, “An Integrative Review of Sibling Responses to Childhood Cancer,” Journal of Child and Adolescent Psychiatric Nursing 31 (2018):109-119, doi: 10.1111/jcap.12219.
  204. “Oncology (Cancer) / Hematologic Malignancies Approval Notifications,” U.S. Food and Drug Administration, accessed December 10, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications.
  205. “Pediatric Oncology Drug Approvals,” U.S. Food and Drug Administration, accessed December 10, 2025, https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals.
  206. Dylan Neel et al., “Timing of First-in-Child Trials Of FDA-Approved Oncology Drugs,” European Journal of Cancer 112 (2019): 49–56, https://doi.org/10.1016/j.ejca.2019.02.011.
  207. Search results for older-adult studies recruiting in the United States, ClinicalTrials.gov, National Library of Medicine, accessed December 10, 2025, https://clinicaltrials.gov/search?aggFilters=ages:adult%20older,status:rec&locStr=United%20States&country=US.
  208. Search results for child-age, recruiting studies in the United States, ClinicalTrails.gov, National Library of Medicine, accessed December 10, 2025, https://clinicaltrials.gov/search?aggFilters=ages:child,status:rec&locStr=United%20States&country=US.
  209. Ian T. T. Liu and Aaron S. Kesselheim, “The RACE Act and Pediatric Trials of Adult Cancer Drugs,” Pediatrics 154, no. 4 (2024), https://doi.org/10.1542/peds.2024-066920.
  210. Anna Lee et al., “Nickel and Dimed: Parking Fees at NCI-Designated Cancer Centers,” Journal of Clinical Oncology 38, no. 15_suppl (2020), https://doi.org/10.1200/JCO.2020.38.15_suppl.2029.
  211. Anna Lee et al., “Nickel and Dimed: Parking Fees at NCI-Designated Cancer Centers,” Journal of Clinical Oncology 38, no. 15_suppl (2020), https://doi.org/10.1200/JCO.2020.38.15_suppl.2029.
  212. D. Isabel Petrescu et al., “Preclinical Models for the Study of Pediatric Solid Tumors: Focus on Bone Sarcomas,” Frontiers in Oncology 14 (2024), https://doi.org/10.3389/fonc.2024.1388484.
  213. “An Analysis of the National Cancer Institute’s Investment in Pediatric Cancer Research,” National Cancer Institute, published September 2013, https://www.cancer.gov/types/childhood-cancers/research/pediatric-analysis.pdf.
  214. “NCI Budget Fact Book,” National Cancer Institute, accessed June 15, 2026, https://www.cancer.gov/about-nci/budget/fact-book.
  215. “NCI Budget Fact Book,” National Cancer Institute, accessed June 15, 2026, https://www.cancer.gov/about-nci/budget/fact-book.
  216. “Unlocking Cures for Pediatric Cancer with Artificial Intelligence [Executive order],” The White House, accessed December 10, 2025, https://www.whitehouse.gov/presidential-actions/2025/09/unlocking-cures-for-pediatric-cancer-with-artificial-intelligence/.
  217. “H.R.3391 - Gabriella Miller Kids First Research Act 2.0,” Congress.gov, accessed December 10, 2025, https://www.congress.gov/bill/118th-congress/house-bill/3391.
  218. “Pediatric Cancer Studies: Early Results of the Research to Accelerate Cures and Equity for Children Act,” U.S. Government Accountability Office, accessed December 10, 2025, https://www.gao.gov/products/gao-23-105947.
  219. John Raffensperger, “Max Wilms and His Tumor,” Journal of Pediatric Surgery 50, no. 2 (2015): 356-359, https://pubmed.ncbi.nlm.nih.gov/25638637/.
  220. “Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®) – Health Professional Version,” National Cancer Institute, accessed December 5, 2025, https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq#_551_toc.
  221. Julia Evangelou Strait, “Scientists Reveal How Proteins Drive Growth of Multiple Cancer Types,” Washington University School of Medicine, accessed December 5, 2025, https://medicine.washu.edu/news/scientists-reveal-how-proteins-drive-growth-of-multiple-cancer-types/.
  222. Magali Olivier et al., “TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use,” Cold Spring Harbor Perspectives in Biology 2, no. 1 (2010), doi: 10.1101/cshperspect.a001008.
  223. Xingui Liu and Alessio Ciulli, “Proximity-Based Modalities for Biology and Medicine,” ACS Central Science 9, no. 7 (2023): 1269–1284, https://doi.org/10.1021/acscentsci.3c00395.
  224. Jihane Balla et al. “Antibody Conjugates in Neuroblastoma: A Step Forward in Precision Medicine,” Frontiers in Oncology 15 (2025), https://doi.org/10.3389/fonc.2025.1548524.
  225. Pooja Hingorani et al., “Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium,” Molecular Cancer Therapeutics 21, no. 8 (2022): 1318-1325, doi: 10.1158/1535-7163.MCT-21-0758.
  226. David A. Martínez-Gamboa et al, “CAR T-Cell Therapy Landscape in Pediatric, Adolescent and Young Adult Oncology – A Comprehensive Analysis of Clinical Trials,” Critical Reviews in Oncology/Hematology 209 (2025), https://doi.org/10.1016/j.critrevonc.2025.104648.
  227. Pan, K., et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res 41, 119 (2022). https://doi.org/10.1186/s13046-022-02327-z.
  228. Loretta M. S. Lau et al., “Precision-Guided Treatment in High-Risk Pediatric Cancers,” Nature Medicine 30 (2024): 1913–1922, https://doi.org/10.1038/s41591-024-03044-0.
  229. “Center for Precision Medicine for High-Risk Pediatric Cancer,” Children’s Hospital of Philadelphia, https://www.chop.edu/centers-programs/center-precision-medicine-high-risk-pediatric-cancer.
  230. Marc W. H. Wijnen and Andrew M. Davidoff, “Minimally Invasive Techniques in Pediatric Surgical Oncology,” Surgical Oncology Clinics of North America 30, no. 2 (2021): 417–430, doi: 10.1016/j.soc.2020.11.008.
  231. William W. Spurbeck et al., “Minimally Invasive Surgery in Pediatric Cancer Patients,” Annals of Surgical Oncology 11 (2004): 340–343, https://doi.org/10.1245/aso.2004.04.021.
  232. “Breakthroughs in Pediatric Oncology: Recent Advances in 2024,” TFS HealthScience, accessed December 5, 2025, https://tfscro.com/resources/breakthroughs-in-pediatric-oncology-recent-advances-in-2024/#:~:text=Recent%20advances%20in%20pediatric%20oncology%20include%20the%20development%20of%20liquid,%2Dpass%20whole%2Dgenome%20sequencing.
  233. Feifei Cheng et al., “Circulating Tumor DNA: A Promising Biomarker in the Liquid Biopsy of Cancer,” Oncotarget 19, no. 7 (2016): 48832–48841, doi: 10.18632/oncotarget.9453.
  234. “Breakthroughs in Pediatric Oncology: Recent Advances in 2024,” TFS HealthScience, accessed December 5, 2025, https://tfscro.com/resources/breakthroughs-in-pediatric-oncology-recent-advances-in-2024/#:~:text=Recent%20advances%20in%20pediatric%20oncology%20include%20the%20development%20of%20liquid,%2Dpass%20whole%2Dgenome%20sequencing.
  235. Bram De Wilde et al., “The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions,” Journal of Clinical Oncology 40, no. 29 (2022), doi: 10.1200/ JCO.22.00033.
  236. Yimei Li et al., “Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics,” Therapeutic Innovation & Regulatory Science 58, no. 4 (2024): 634–644, doi: 10.1007/s43441-024-00656-z.
  237. Jingjing Ye et al., “A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials,” Pharmaceutical Statistics 19, no. 6 (2020): 814-826, doi: 10.1002/pst.2039.
  238. Howard (Jack) West, “Novel Precision Medicine Trial Designs: Umbrellas and Baskets,” JAMA Oncology 3, no. 3 (2017): 423, doi:10.1001/jamaoncol.2016.5299.
  239. Bram De Wilde et al., “The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions,” Journal of Clinical Oncology 40, no. 29 (2022), doi: 10.1200/ JCO.22.00033.
  240. “Unlocking Cures for Pediatric Cancer with Artificial Intelligence,” The White House, accessed December 5, 2025, https://www.whitehouse.gov/presidential-actions/2025/09/unlocking-cures-for-pediatric-cancer-with-artificial-intelligence/.
  241. “The Potential Role of Artificial Intelligence in Transforming Childhood Cancer Care,” eClinicalMedicine 72 (2024), https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00284-0/fulltext.
  242. “Trends in Survivorship Grant Funding,” National Cancer Institute, accessed December 5, 2025, https://cancercontrol.cancer.gov/ocs/funding/trends-survivorship-grant-funding.
  243. “Childhood Cancer STAR (Survivorship, Treatment, Access, Research) Act (Public Law No. 115180) & STAR Reauthorization Act (Public Law No. 117350),” National Cancer Institute, accessed December 5, 2025, https://www.cancer.gov/about-nci/legislative/recent-public-laws/star-act.
Acknowledgments